Expertise in ADCC Characterisation Strategies
No single approach can be applied to characterise the ADCC activity of a biosimilar and a successful ADCC characterisation strategy is dependent upon the (multiple) mechanism of actions of the innovator drug, its approved indications and most importantly, upon the observed activity of the biosimilar candidate itself relative to the reference innovator molecule. An ADCC evaluation strategy must therefore encompass a range of orthogonal analytical techniques that range from relatively simply CD16a (Fcγ Receptor IIIa) binding assessments to cell based ADCC assays. The complexity of ADCC assays can significantly increase as the nature of target and effector cell preparations are varied to meet specific objectives of the characterisation strategy.
Our experts have an unparalleled understanding of ADCC assay performance combined with industry leading expertise in the design and implementation of ADCC characterisation strategies. With knowledge gleaned from different biosimilar molecules that demonstrate a diverse range of similarity relative to the reference innovator product, we can help define a successful ADCC characterisation strategy for your biosimilar and perform the required experiments.
Our ADCC characterisation services include CD16a (Fcγ Receptor IIIa) binding assays, cell based binding assays (ELISA and Flow Cytometry) for measurement of antibody-antigen at the cell membrane and a range of methods based upon the advanced ADCC assay platform and a diverse range of investigatory ADCC assay formats that, together, are designed to truly understand the biological relevance and clinical significance of differences in ADCC activity. We provide ADCC characterisation services for the following biosimilar molecules.
To discuss our wide range of ADCC formats, cell based binding and CD16a binding assays please click here to contact us